Migraine Headache Clinical Trial
Official title:
Effectiveness of Integrated Education and Relaxation Program on Migraine Related Disability in Patients Attending Headache Clinic, Ain Shams University Hospitals: A Randomized Controlled Trial
Verified date | August 2021 |
Source | Ain Shams University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Migraine causes severe impairment in quality of life (QOL) both during and between attacks. Migraine also increases absenteeism, reduces productivity at work as well as at home, disrupts social and family relationships, also is associated with increased healthcare costs. The current study aiming to evaluate the effectiveness of an integrated therapeutic patient education and relaxation training intervention in order to decrease the burden of migraine headache among adult patients attending the headache clinic in Ain Shams University Hospitals.
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | June 2022 |
Est. primary completion date | September 13, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Aged 18-65 years old. - Diagnosed with migraine for at least 6 months duration. - Experiencing 4 or more migraine days/month with disability. - Willingness to practice relaxation exercises at home. Exclusion Criteria: - Secondary headache. - Patients with severe co-morbid psychiatric (depression, anxiety), personality or medical condition (liver or renal impairments). |
Country | Name | City | State |
---|---|---|---|
Egypt | Faculty of Medicine | Cairo |
Lead Sponsor | Collaborator |
---|---|
Ain Shams University |
Egypt,
Eghbal Sekhavati, Mojtaba Rahimian Boogar, Rouhi Afkari, Somayeh Kasharafifard, Vahideh Parsaei Mehr, Fatemeh Lotfi Mola and Kobra Ahanijegar, 2016. The Study of the Effectiveness of Progressive Muscle Relaxation to Reduce Symptoms in Women with Migraine Headache. Research Journal of Medical Sciences, 10: 175-184.
Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, D'Amico D, Diener HC, Hansen JM, Lanteri-Minet M, Loder E, McCrory D, Plancade S, Schwedt T; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012 Jan;32(1):6-38. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effectiveness of the intervention program on headache frequency | Attacks frequency, expressed in days per month , will be collected from the "headache diary" filled in by the patient.
Data will be recruited from the diary at base line and after another 4 weeks, Final evaluation will be done after 3 month |
3 month | |
Primary | Effectiveness of the intervention program on headache intensity | The average of monthly attacks intensity ( severity) will be measured using the (Numerical rating scale) (from 0 to 10 scales) included in the headache diary Data will be recruited from the diary at base line and after 4 weeks, Final evaluation will be done after 3 month from beginning of the intervention program | 3 month | |
Primary | Effectiveness of the intervention program on headache (attacks) duration | The average of monthly attacks duration will be calculated from the headache diary filled in by the patient at base line,4 weeks and finally after 3 month from the baseline evaluation | 3 month | |
Secondary | Effectiveness of the intervention program on headache related quality of life and disability | By using the "Migraine specific quality of life questionnaire (MSQ)": The MSQ is a 14-items measure designed to assess the effects of migraine on an individual's quality of life. There are three MSQ subscales, Emotional (MSQ-E), restrictive (MSQ-R), and preventive (MSQ-P). The MSQ is a reliable and valid questionnaire in migraine patients that can determine the functional impact of migraine.
Evaluation of both groups will be done using "MSQ questionnaire" at base line and after another 4 weeks, Final evaluation will be done after 3 month from base line by the researcher using the same tool. |
3 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Not yet recruiting |
NCT05943457 -
Vitamin K2 Supplementation in Adult Episodic Migraine
|
N/A | |
Completed |
NCT01211145 -
Zomig - Treatment of Acute Migraine Headache in Adolescents
|
Phase 4 | |
Completed |
NCT00530517 -
A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack
|
Phase 2 | |
Completed |
NCT00898677 -
Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
|
Phase 3 | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Completed |
NCT03971071 -
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
|
Phase 4 | |
Withdrawn |
NCT02706015 -
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks
|
Phase 3 | |
Terminated |
NCT02375789 -
Intranasal Cooling for Symptomatic Relief of Migraine
|
N/A | |
Completed |
NCT02518464 -
Ticagrelor Therapy for RefrACTORy Migraine Study
|
Phase 4 | |
Terminated |
NCT00391755 -
A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches
|
Phase 4 | |
Completed |
NCT03401346 -
Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults
|
Phase 1 | |
Completed |
NCT05085483 -
Ketone for Migraine Prevention
|
N/A | |
Completed |
NCT01604785 -
Low-dose Propofol for Pediatric Migraine
|
Phase 2/Phase 3 | |
Terminated |
NCT00804973 -
Study in Participants With Acute Migraines Headaches
|
Phase 2 | |
Completed |
NCT03341689 -
Psilocybin for the Treatment of Migraine Headache
|
Phase 1 | |
Completed |
NCT01630044 -
Neurostimulation Device for Treatment of Migraine Headache
|
N/A | |
Active, not recruiting |
NCT00285402 -
Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine
|
Phase 2 | |
Completed |
NCT00203255 -
Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache
|
N/A | |
Recruiting |
NCT06046508 -
Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)
|